Navigation Links
Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
Date:11/28/2012

SOUTH EASTON, Mass., Nov. 28, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Ironridge BioPharma Co. ("Ironridge") has converted their remaining 200 shares of the Company's Series E Convertible Preferred Stock (the "Series E Preferred Stock") into shares of the Company's common stock.  Following this conversion, all 500 shares of Series E Preferred Stock purchased by Ironridge in the April 2012 $500,000 registered direct transaction with the Company have been converted.  

The total number of shares of common stock issued to Ironridge for their Series E Preferred Stock investment was 1,113,033, of which 688,378 were reflected in the 11,189,612 shares issued and outstanding on September 30, 2012, as set forth in the Company's third quarter financial statements accompanying our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  In connection with the Series E Preferred Stock transaction, the Company paid the make-whole dividend with a combination of cash and common stock.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "We greatly appreciate the investment made by Ironridge this past April.  The funds received were used in part to support the new marketing and sales program that we introduced earlier this year.  We believe this program played an important role in helping us achieve record PCT Products revenue in the third quarter of 2012, and will also play an important role in our anticipated future revenue growth.  We also appreciate Ironridge's open dialogue and support, as their cooperation helped ensure a smooth and mutually beneficial transaction."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
2. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
3. Convenient New iHealth Blood Pressure Monitors and Body Analysis Scale Now Available for Purchase at Major Retailers and Online
4. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
5. Keynote Presentation at Upcoming International Microbiology & Genomics Meeting to Highlight Ability of Pressure BioSciences Patented PCT Platform to Improve Testing for Biological Threat Organisms, Human Infectious Diseases, and Contaminated Food P
6. South and Central America Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multiparameter Patient Monitoring, Neonatal Monitors, Non-Invasive Blood Pressure Monitors and Others
7. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
8. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
9. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
10. Long-Term Use of Blood Pressure Medications that Promote Sun Sensitivity May Increase Risk of Lip Cancer in Non-Hispanic Whites
11. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 Today, Wall Street Reports announced ... GILD ), Health Management Associates Inc. (NYSE: HMA ... Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius Therapeutics ... of charge - including full price targets, industry analysis and ... Sciences, Inc. Research Report On June 7, 2013, ...
(Date:6/18/2013)... And EMERYVILLE, Calif. ... Inc. presented final results today from a Phase ... release) capsules demonstrating a statistically significant improvement in ... baseline at week 8 versus placebo in the ... investigational extended-release formulation of amantadine intended for once-nightly ...
(Date:6/18/2013)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... general corporate update in conjunction with its 2013 Annual Meeting ... 2:10 p.m. Pacific Time in Carlsbad, CA. ... follows: 2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders ... 2:10 p.m. – 3:15 p.m. Corporate Presentation – Stanley ...
Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... cells have a much different and more complex ... University of Texas at Dallas have found that exploiting ... lung cancer. , In an article published online May ... Dallas researchers compared the metabolic characteristics of non-small-cell lung ... same patient. , They found that the cancer ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ages 13 ... for Disease Control and Prevention (CDC). Of those, nearly 20 ... HIV Testing Day on June 27, Allsup, a nationwide provider ... CDC and other organizations are raising awareness of the importance ... new HIV infections each year. Along with developing AIDS, those ...
Breaking Medicine News(10 mins):Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3
... , , , ... Sterling Communications Inc. , an independent, full-service, high-tech ... Knome to its client portfolio of industry-leading technology ... Knome has turned to Sterling to create a communications strategy ...
... , , , OCEANSIDE, N.Y., ... DEKAYE Consulting, Inc., announced the publication of his newest article, ... in the June 30, 2009 and July 14, 2009 issues of ... 12-13 and 12-14). Mr. DeKaye serves on the publication,s editorial ...
... Aug. 3, 2009 The new anti-wrinkle facial filler Dysport, ... reduced frown lines between the eyes, according to users and ... Southwestern Medical Center. "Our study confirmed that Dysport (abobotulinumtoxinA) ... Dr. Rod Rohrich, chairman of plastic surgery at UT Southwestern ...
... study finding suggests insulin treatment could boost the risk ... of the most widely used diabetes drugs, may offer ... pancreatic cancer by 60 percent, a new study shows. ... treatments, including the use of insulin or insulin-releasing medications ...
... , , LAS VEGAS, ... that expressdelivery.biz is a trusted merchant and its ability to honor ... have been verified by buySAFE. This certificate from the all-bonded online ... reliable and smooth online purchases with bond guarantees of up to ...
... , , CHICAGO, July 30 ... the leading global provider of risk management ... and Beverage Industry Report . The first annual report was ... remain abreast of emerging issues and learn how peers and competitors ...
Cached Medicine News:Health News:Knome Selects Sterling Communications as Agency of Record 2Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 2Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 3Health News:New DeKaye Article Identifies 'Hierarchy of Greed' in Healthcare Fraud 4Health News:Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:US Discount Online Pharmacy Expressdelivery.biz Can Guarantee Safe and Enjoyable Shopping Experience With buySAFE Certificate 2Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 2Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 3Health News:Increasing Regulation and Economic Volatility Key Catalysts for Risk Management in the Food System, Agribusiness and Beverage Industry, Says Report from Aon Analytics 4
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
Inquire...
... 10.1 kg, Interior Dimensions (WxDxH): 31.1 x ... (WxDxH): 44.6 x 22.4 x 20.5 cm, ... 2 - 300 x 35 mm bottles, ... or 1 - 240 x 80 mm ...
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
Medicine Products: